• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, August 26, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

ACP releases paper on methods for developing evidence-based clinical policy papers

Bioengineer by Bioengineer
June 11, 2019
in Cancer
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

ACP continues to refine and enhance methodology for guidelines and guidance statements

Philadelphia, June 11, 2019 – Recommendations for the screening, diagnosis, and treatment of various diseases often differ by organization, making it difficult to know which ones to follow. To help doctors and patients understand how high-quality, evidence-based recommendations are developed and inform their decisions, the American College of Physicians (ACP) has released a paper, published in Annals of Internal Medicine, that presents ACP’s methods for developing two types of clinical policy papers relevant to internal medicine: clinical guidelines and guidance statements.

“The hallmark of ACP’s methodology is that we base our clinical guidelines and guidance statements on the best available scientific evidence,” said ACP President Robert M. McLean, MD, FACP. “It is important for physicians, other clinicians, patients, and caregivers to know that ACP uses rigorous standards to ensure the production of trustworthy, high quality, and useful clinical policy papers and recommendations.”

ACP’s methodology meets the standards of the Guidelines International Network and the National Academy of Medicine. Recent enhancements include more stringent disclosure of interest and conflict management policies; inclusion of public members (individuals who are not physicians) and their perspective; full adoption of Grading of Recommendations Assessment, Development and Evaluation (GRADE) methods; standardized reporting formats that consider value of care, patients with multiple chronic diseases, patient values and preferences, and costs; and further clarification on guidance statement methods.

Clinical guidelines are developed based on a systematic review of the available evidence. Evidence-to-decision tables following the GRADE framework serve as the roadmap for documenting decisions and evidence behind the final recommendations. ACP considers clinical benefits and harms of an intervention and variations in patient values and preferences in deliberations about recommendations for each guideline. ACP also considers costs and burden of care when assessing health care value and developing recommendations.

Guidance statements are developed on topics where several clinical guidelines issued by other organizations are available but are conflicting. The aim of ACP guidance statements is to reconcile clinical guidelines to help physicians provide evidence-based care for their patients. ACP reviews the available clinical guidelines and their evidence base, and develops subsequent guidance based on an assessment of the reported benefits, harms, costs, and patient preferences and values from the assessed guidelines and their evidence.

ACP develops its clinical policy papers through its Clinical Guidelines Committee (CGC), a multidisciplinary group of 14 members, 12 of whom are physicians representing general internal medicine and internal medicine subspecialties (e.g., geriatrics, nephrology, rheumatology, pulmonology, and hospital medicine). The CGC also includes two non-physician public members with equal standing and terms as the physician members, including voting and authorship privileges.

“The Development of Clinical Guidelines and Guidance Statements by the Clinical Guidelines Committee of the American College of Physicians” also explains in detail ACP’s disclosure of financial and intellectual interests and management of conflicts policy; the review and approval process of clinical guidelines and guidance statements to become ACP policy; how ACP publishes its clinical guidelines and guidance statements; and how the development of ACP clinical guidelines, guidance statements, and commissioned evidence reviews are financed.

###

ACP is a well-recognized name in evidence-based medicine. ACP is member of the Guidelines International Network, whose mission is to lead, strengthen, and support collaboration in guideline development, Cochrane, a global leader and resource in evidence-informed health decision-making, has officially recognized ACP as a Cochrane US Network Affiliate. To receive such a designation, Affiliates must show a proven record of supporting evidence-based practice and expertise and competencies in systematic reviewing and evidenced-informed health practice and policy.

About the American College of Physicians

The American College of Physicians is the largest medical specialty organization in the United States with members in more than 145 countries worldwide. ACP membership includes 154,000 internal medicine physicians (internists), related subspecialists, and medical students. Internal medicine physicians are specialists who apply scientific knowledge and clinical expertise to the diagnosis, treatment, and compassionate care of adults across the spectrum from health to complex illness.

Media Contact
Steve Majewski
[email protected]
http://dx.doi.org/10.7326/M18-3290

Tags: cancerCardiologyClinical TrialsEndocrinologyInternal MedicineMedicine/HealthMetabolism/Metabolic Diseases
Share12Tweet7Share2ShareShareShare1

Related Posts

Higher Skin Autofluorescence Signals Cancer Risk

August 26, 2025

Exploring Retinoblastoma Biomarkers: A Decade of Research

August 26, 2025

Cyclin-Dependent Kinase 4/6 Inhibitors Boost Immunotherapy

August 26, 2025

Afatinib Trial Targets Fanconi Anemia Cancer

August 26, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    147 shares
    Share 59 Tweet 37
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    142 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    115 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Unseen Whirlwinds: Researchers Discover ‘Hidden’ Vortices That May Impact Soil and Snow Movement

Higher Skin Autofluorescence Signals Cancer Risk

Spatial Cues Drive Multiplexed Theta Coding

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.